Bellicum is a clinical-stage biopharmaceutical company that is driving the future of cellular immuno-oncology (IO). We discover and develop product candidates in some of the most important areas of cellular immunotherapy, with a focus on CAR-T therapies.
Bellicum has engineered the next wave of high-performance cellular technology, unleashing the power of potentially curative IO therapies against a wide range of cancers, providing a better tomorrow for more cancer patients.